This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML | MicrobiomeTrials
← Back to trials NCT04588922
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML Recruiting PHASE1, PHASE2 INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2021-05-10Est. Completion: 2026-12-30
Enrollment target: 160 participantsLocations O'Neal Comprehensive Cancer Center, University of Alabama, Birmingham, Alabama, United States City of Hope - Phoenix, Goodyear, Arizona, United States City of Hope National Medical Center, Duarte, California, United States Moffitt Cancer Center, Tampa, Florida, United States City of Hope - Atlanta, Newnan, Georgia, United States City of Hope - Chicago, Zion, Illinois, United States Ochsner Clinic Foundation, New Orleans, Louisiana, United States Clinical Research Alliance, Inc., Lake Success, New York, United States New York - Presbyterian Hospital, New York, New York, United States UNC School of Medicine, Division of Hematology, Chapel Hill, North Carolina, United States Bon Secours St. Francis Cancer Center, Greenville, South Carolina, United States Baylor Scott & White Health, Dallas, Texas, United States MD Anderson, Houston, Texas, United States The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China Anhui Provincial Hospital, Hefei, Anhui, China Affiliated Cancer Hospital of Chongqing University, Chongqing, Chongqing Municipality, China Other microbiome trials you might be interested in Nephropathic Cystinosis
An open-label, multi-center, phase I/II study to assess the safety, tolerability and efficacy of DFT383 in pediatric par…
San Diego, United States Est. completion May 28, 2031
Multiple Myeloma
To evaluate the overall response rate, safety, and the 12-cycle clearance rate of circulating plasma cells (CPCs) in pat…
Multiple Locations Est. completion Aug 1, 2028
Cancer prevention and treatment center of Sun Yat sen University, Guangzhou, Guangdong, China
Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
Affiliated Hospital of Hebei University, Baoding, Hebei, China
Henan Cancer Hospital, Zhengzhou, Henan, China
The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
The First Affiliated Hospital Of Nanchang University, Nanchang, Jiangxi, China
Shengjing Hospital Affiliated to China Medical University, Shenyang, Liaoning, China
Linyi Cancer Hospital, Linyi, Shandong, China
Blood disease hospital, Chinese Academy of Medical Science, Tianjin, Tianjin Municipality, China
The Second Affiliated hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China